| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The specific molecular targets of Oxyphyllacinol are not fully defined, but it is known to exhibit neuroprotective, antioxidant, and anti-aging activities. Its effects are likely mediated through multiple pathways, including modulation of oxidative stress and inflammation. Its mechanism of action is an active area of research.
|
|---|---|
| ln Vitro |
In vitro, Oxyphyllacinol has demonstrated neuroprotective effects. It is studied for its potential antioxidant and anti-aging activities, suggesting it can protect cells from oxidative damage. These in vitro studies provide evidence for its potential therapeutic benefits.
|
| ln Vivo |
In vivo, Oxyphyllacinol is studied in animal models of dementia and other neurological disorders. Its neuroprotective effects are evaluated by assessing cognitive function and neuronal survival. These studies are crucial for understanding its potential as a therapeutic agent for neurodegenerative diseases.
|
| Enzyme Assay |
In vitro assays would involve measuring the compound's ability to scavenge free radicals or to protect neuronal cells from oxidative stress-induced damage. Its effect on cellular pathways related to aging and neurodegeneration can also be assessed.
|
| Cell Assay |
Neuronal cell lines are treated with Oxyphyllacinol, and cell viability is measured under conditions of oxidative stress. Markers of neuroprotection and antioxidant activity are quantified to assess its efficacy. These cellular assays help to elucidate the compound's mechanism of action.
|
| Animal Protocol |
Animal models of dementia, such as chemically induced or transgenic mouse models, are used to study the in vivo effects of Oxyphyllacinol. Cognitive tests and histological analysis of brain tissue are performed. These studies are essential for evaluating its potential as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies would investigate the absorption, distribution, metabolism, and excretion of Oxyphyllacinol. Its ability to cross the blood-brain barrier is a key parameter for its potential use in CNS disorders.
|
| Toxicity/Toxicokinetics |
Toxicology studies would evaluate the safety profile of Oxyphyllacinol. As a natural product, its safety is of interest, but formal toxicological evaluation would be necessary for development as a therapeutic.
|
| References | |
| Additional Infomation |
Reports indicate that Oxyphyllacinol has been found in Alpinia oxyphylla, and relevant data are available for reference.
Oxyphyllacinol is a natural product derived from the fruit of Alpinia oxyphylla. It is used in research as a potential neuroprotective agent for the treatment of dementia and other neurodegenerative diseases. It is a compound of interest for its potential health benefits. |
| Molecular Formula |
C20H26O3
|
|---|---|
| Molecular Weight |
314.418646335602
|
| Exact Mass |
314.19
|
| Elemental Analysis |
C, 76.40; H, 8.34; O, 15.27
|
| CAS # |
87657-77-0
|
| Related CAS # |
87657-77-0
|
| PubChem CID |
5320349
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
23
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)CCC(CCCCC2=CC=CC=C2)O)O
|
| InChi Key |
DHUCMVAZNHOIPY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H26O3/c1-23-20-15-17(12-14-19(20)22)11-13-18(21)10-6-5-9-16-7-3-2-4-8-16/h2-4,7-8,12,14-15,18,21-22H,5-6,9-11,13H2,1H3
|
| Chemical Name |
4-(3-hydroxy-7-phenylheptyl)-2-methoxyphenol
|
| Synonyms |
Oxyphyllacinol; Benzenepentanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~318.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1805 mL | 15.9023 mL | 31.8046 mL | |
| 5 mM | 0.6361 mL | 3.1805 mL | 6.3609 mL | |
| 10 mM | 0.3180 mL | 1.5902 mL | 3.1805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
